Among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC), treatment with vandetanib demonstrates anti-tumor activity and a manageable safety profile, according to a study published in The Lancet Respiratory Medicine.1

Researchers led by Kiyotaka Yoh, MD, of the National Cancer Center Hospital East in Chiba, Japan, evaluated results from the phase 2 LURET trial, which enrolled 19 patients with advanced RET-rearranged NSCLC who received oral vandetanib continuously at 300 mg every day.

Seventeen patients were included in the primary analysis, of which 9 were able to achieve the primary endpoint of objective response. Nine patients achieved objective response in an intention-to-treat population analysis.

Median progression-free survival was 4.7 months at the data cutoff. Common adverse events included hypertension, diarrhea, and rash.

RELATED: Adding Nintedanib to Pemetrexed Prolonged PFS in Advanced Non-squamous NSCLC

“Our results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy,” the authors conclude.

Reference

  1. Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2016 Nov 4. doi: 10.1016/S2213-2600(16)30322-8 [Epub ahead of print]